Tonix Q4 2023 net loss $27.3M; cash down to $24.9M; Tonmya NDA on track for H2 2024

Tonix Pharmaceuticals Holding Corp.

2024-Q1 EPS reported -$0.18 revenue$2,482,000

Q4 2023 net loss $27.3M ($0.86/share) vs $34.1M ($3.42) in Q4 2022; full year net product revenue $7.8M.
Cash and equivalents $24.9M at Dec 31, 2023 vs $120.2M at Dec 31, 2022; net cash used in operations $102M.
Pre-NDA meeting with FDA for Tonmya (cyclobenzaprine SL) for fibromyalgia scheduled Q2 2024; NDA submission planned H2 2024.
Raised $4.4M in registered direct offering on March 28, 2024; also $11M term loan executed Dec 2023.
Completed transition to fully integrated pharma with marketed migraine products Zembrace and Tosymra.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Tonix Pharmaceuticals Holding Corp. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On April 1, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter and year ended December 31, 2023.

View on SEC.gov

324 earnings releases filed in the last 30 days. Browse all earnings releases →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001999371-24-004298

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.